3 - MyMD Pharmaceuticals, Inc. (0001321834) (Issuer)

4 - MyMD Pharmaceuticals, Inc. (0001321834) (Issuer)

3 - MyMD Pharmaceuticals, Inc. (0001321834) (Issuer)

4 - MyMD Pharmaceuticals, Inc. (0001321834) (Issuer)

3 - MyMD Pharmaceuticals, Inc. (0001321834) (Issuer)

4 - MyMD Pharmaceuticals, Inc. (0001321834) (Issuer)

4 - MyMD Pharmaceuticals, Inc. (0001321834) (Issuer)

4 - MyMD Pharmaceuticals, Inc. (0001321834) (Issuer)

3 - MyMD Pharmaceuticals, Inc. (0001321834) (Issuer)

3 - MyMD Pharmaceuticals, Inc. (0001321834) (Issuer)

Shares to commence trading on the Nasdaq Capital Market on April 19, 2021 under the new ticker symbol "MYMD" Upon Closing, the Combined Company will focus on developing and commercializing novel immunotherapy pipeline assets, including its lead molecule MYMD-1 Recently announced plans to initiate Phase 2 trial Akers Biosciences, Inc. ("Akers") (NASDAQ:AKER) and MyMD Pharmaceuticals, Inc. ("MYMD") today announced that at Akers' special meeting of stockholders held on April 15, 2021, Akers obtained sufficient votes for each proposal required to consummate the previously announced proposed merger between Akers and MYMD. MYMD previously obtained a sufficient number of written consents fr

Akers Biosciences, Inc. (NASDAQ:AKER), today announced that its proposed merger partner MyMD Pharmaceuticals, Inc. ("MyMD"), a clinical stage pharmaceutical company committed to extending health lifespan and treating immune mediated illnesses, has reached an agreement with a major medical school to conduct a Phase 2 clinical trial to investigate the effectiveness of MYMD-1 to treat immune mediated depression in patients affected with COVID-19. MYMD believes that this investigator-initiated study is the first of its kind and addresses a significant unmet medical need. In a finding published in JAMA Network Open on 3/12/21, it was found that 52% of individuals who had COVID-19 had an associa

Chaired by Katharine Whartenby, Ph.D., members include experts in molecular medicine, aging, pathology and oncology Akers Biosciences, Inc. (NASDAQ:AKER), today announced that its proposed merger partner MyMD Pharmaceuticals, Inc. ("MyMD"), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, has completed the formation of its Scientific Advisory Board (SAB). The board will be chaired by Katharine Whartenby, Ph.D., associate professor at the Johns Hopkins University School of Medicine Department of Neurology, Department of Oncology and in Cellular and Molecular Medicine. "Each member of our Scientific Adviso

BALTIMORE & THOROFARE, N.J.--(BUSINESS WIRE)--Akers Biosciences, Inc (Nasdaq: AKER), today announced that it has scheduled its general meeting of shareholders (the "Meeting”) to vote on the proposed business combination with MyMD Pharmaceuticals (“MyMD”). The meeting will be held on April 15, 2021 at 10:00 a.m., Eastern Time, and will be “virtual,” meaning that you can participate in the meeting online at www.virtualshareholdermeeting.com/AKER2021SM. In connection with the Meeting, Akers’ board of directors has fixed the close of business on March 15, 2021 as the record date for the special meeting. “We believe the strategic combination of Akers with MyMD has the potential to ac

BALTIMORE--(BUSINESS WIRE)--Akers Biosciences, Inc. (Nasdaq: AKER), with its proposed merger partner MyMD Pharmaceuticals, Inc. (“MyMD”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today announced new data from a study conducted by Eurofins Discovery Phenotypic Center of Excellence. MYMD-1 is being developed to treat autoimmune and age-related diseases, including extending the human lifespan, and has been shown to be effective in regulating the immune system in preclinical studies. The findings of the Eurofins Discovery study indicate the potential of MYMD-1 to limit the fibrotic biology as

BALTIMORE--(BUSINESS WIRE)--Akers Biosciences, Inc. (Nasdaq: AKER), with its proposed merger partner MyMD Pharmaceuticals, Inc. (“MyMD”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today announced a new study published in PLOS ONE authored by Adam Kaplin, M.D., Ph.D., Chief Scientific Officer of MyMD Pharmaceuticals, which demonstrates rising temperatures during spring and summer months are associated with slower rates of COVID-19 transmission, consistent with the behavior of a seasonal respiratory virus. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) belongs to a large

New York, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Breath Analyzer Market Research Report by Technology, by Application, by End User - Global Forecast to 2025 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p05993415/?utm_source=GNW pylori Infection Detection, and Tuberculosis Detection), by End User - Global Forecast to 2025 - Cumulative Impact of COVID-19The Global Breath Analyzer Market is expected to grow from USD 1,432.85 Million in 2019 to USD 3,418.97 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 15.59%.Market Segmentation & Coverage:This research report categorizes the Breath Analyzer to forecast

S-3/A - MyMD Pharmaceuticals, Inc. (0001321834) (Filer)

8-K - MyMD Pharmaceuticals, Inc. (0001321834) (Filer)

8-K - Akers Biosciences, Inc. (0001321834) (Filer)

425 - Akers Biosciences, Inc. (0001321834) (Subject)

425 - Akers Biosciences, Inc. (0001321834) (Subject)

EFFECT - Akers Biosciences, Inc. (0001321834) (Filer)

424B3 - Akers Biosciences, Inc. (0001321834) (Filer)

425 - Akers Biosciences, Inc. (0001321834) (Subject)

8-K - Akers Biosciences, Inc. (0001321834) (Filer)

S-4/A - Akers Biosciences, Inc. (0001321834) (Filer)

SC 13G/A - Akers Biosciences, Inc. (0001321834) (Subject)

SC 13G - Akers Biosciences, Inc. (0001321834) (Subject)